{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:09:37Z","timestamp":1793376577040,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Carbapenem-resistant multidrug-resistant (MDR) and pandrug-resistant (PDR) Gram-negative infections represent a critical therapeutic challenge in pediatric intensive care units (PICUs), where effective treatment options are extremely limited. This study aimed to describe the real-world clinical outcomes and safety of ceftazidime\u2013avibactam (CZA) in critically ill children with MDR\/PDR infections. We conducted a retrospective observational study of pediatric patients aged 1\u00a0month to 18\u00a0years who received CZA for microbiologically confirmed MDR or PDR Gram-negative infections in a tertiary PICU between February 2021 and January 2025. Twenty-one critically ill children (median age 55\u00a0months, IQR 11\u2013126) were included; two-thirds had underlying chronic conditions and 23.8% were immunosuppressed.\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    was the predominant pathogen (85.7%). Microbiological clearance in follow-up cultures was observed in 85.7% of patients with available microbiological data, and clinical improvement was noted in most patients in this critically ill population. Infection-related mortality was 19% and was primarily associated with host-related factors, including younger age and immunosuppression. Resistance emergence during therapy was observed in one patient. Such resistance development during CZA treatment has been reported rarely in the literature and may involve mechanisms such as mutations in carbapenemase enzymes or alterations in bacterial permeability. In our study, resistance was detected during ongoing therapy in a single patient with\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    , highlighting the importance of close microbiological monitoring in critically ill patients receiving prolonged treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    :\u00a0CZA was used as a salvage treatment in critically ill children with MDR and PDR Gram-negative infections, with favorable clinical and microbiological outcomes observed. These real-world data support its cautious incorporation into pediatric antimicrobial stewardship strategies in PICU settings.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              \u2022\n                              <jats:italic>Ceftazidime\u2013avibactam is a promising agent against carbapenem-resistant Enterobacterales in adults.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Pediatric data remain limited, especially in critically ill children with MDR or PDR infections.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              \u2022\n                              <jats:italic>Ceftazidime\u2013avibactam was used as salvage therapy for multidrug- and pandrug-resistant Gram-negative infections in critically ill children.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Clinical and microbiological response was achieved in a high-risk PICU population despite prolonged hospitalization and extensive prior antibiotic exposure.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-026-06862-1","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:38:50Z","timestamp":1774579130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ceftazidime\u2013avibactam for multidrug and pandrug-resistant gram-negative infections in critically Ill children: a single-center pediatric \u0131ntensive care experience"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-7906","authenticated-orcid":false,"given":"Merve","family":"Havan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-5945","authenticated-orcid":false,"given":"G\u00fcl","family":"Arga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"B\u00fclb\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"\u00d6zerdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-7382","authenticated-orcid":false,"given":"Eda","family":"Eyduran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-5652","authenticated-orcid":false,"given":"Ay\u015fen Durak","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-2437","authenticated-orcid":false,"given":"Nilay","family":"Penezo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-414X","authenticated-orcid":false,"given":"Hatice Belk\u0131s","family":"\u0130nceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-267X","authenticated-orcid":false,"given":"Duygu","family":"\u00d6cal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-1688","authenticated-orcid":false,"given":"Halil","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4955-160X","authenticated-orcid":false,"given":"Ergin","family":"\u00c7iftci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-2803","authenticated-orcid":false,"given":"Tan\u0131l","family":"Kendirli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"suppl_1","key":"6862_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/infdis\/jiw282","volume":"215","author":"LK Logan","year":"2017","unstructured":"Logan LK, Weinstein RA, Bonomo RA, Tolmasky ME, Paterson DL, Nordmann P, Bradford PA, Cant\u00f3n R, Pitout JDD, Livermore DM (2017) The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215(suppl_1):28\u201336","journal-title":"J Infect Dis"},{"issue":"11","key":"6862_CR2","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3201\/eid2011.140206","volume":"20","author":"S Bialek-Davenet","year":"2014","unstructured":"Bialek-Davenet S, Criscuolo A, Ailloud F, Passet V, Jones L, Delannoy-Vieillard AS, Diancourt L, Arlet G, Brisse S (2014) Genomic definition of hypervirulent and multidrug-resistant Klebsiella pneumoniae clonal groups. Emerg Infect Dis 20(11):1812\u20131820","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"6862_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ, Simner PJ, Pogue JM, Kaye KS, Rodriguez-Ba\u00f1o J (2021) Infectious Diseases Society of America guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis 72(7):169\u2013183","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6862_CR4","volume":"6","author":"FS Codjoe","year":"2017","unstructured":"Codjoe FS, Donkor ES, Nii-Trebi N, Osei I, Adu-Gyamfi E, Tetteh-Quarcoo PB (2017) Carbapenem resistance: a review. Med Sci (Basel) 6(1):1","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"6862_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13070598","volume":"13","author":"M Garc\u00eda-Boyano","year":"2024","unstructured":"Garc\u00eda-Boyano M, P\u00e9rez-Garc\u00eda R, L\u00f3pez-Calleja AI, Rodr\u00edguez-Lucas M, Garc\u00eda-Mu\u00f1oz \u00c1, S\u00e1nchez-Romero I, L\u00f3pez-Gonz\u00e1lez M, Garc\u00eda-Rodr\u00edguez J, Rodr\u00edguez-Ba\u00f1o J, Palacios-Baena ZR (2024) Ceftazidime\u2013avibactam use in a case series of difficult-to-treat or recurrent infections in pediatric patients. Antibiotics (Basel) 13(5):598","journal-title":"Antibiotics (Basel)"},{"issue":"6","key":"6862_CR6","volume":"11","author":"AR da Araujo Silva","year":"2024","unstructured":"da Araujo Silva AR, Quijada R, Rodr\u00edguez-Fern\u00e1ndez A, Garc\u00eda-Garc\u00eda MI, L\u00f3pez-Calleja AI, Garc\u00eda-Boyano M, Palacios-Baena ZR, Rodr\u00edguez-Ba\u00f1o J (2024) Use of ceftazidime\u2013avibactam in children admitted to pediatric intensive care units. Children (Basel) 11(6):664","journal-title":"Children (Basel)"},{"key":"6862_CR7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2147\/IDR.S426326","volume":"16","author":"H Meng","year":"2023","unstructured":"Meng H, Zhang Y, Li X, Wang Y, Liu J, Chen Z, Zhao L, Sun Y, Zhou Q, Huang Y (2023) Use of ceftazidime\u2013avibactam for suspected or confirmed carbapenem-resistant organisms in children: a retrospective study. Infect Drug Resist 16:1234\u20131242","journal-title":"Infect Drug Resist"},{"issue":"1","key":"6862_CR8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/s12879-019-4477-2","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Wang J, Li C, Zhang Y, Liu H, Chen X, Zhao M, Sun Q, Yang Z, Xu W (2019) Efficacy of ceftazidime\u2013avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae in children. BMC Infect Dis 19(1):906","journal-title":"BMC Infect Dis"},{"key":"6862_CR9","doi-asserted-by":"publisher","unstructured":"Foo ALA, Young B, Ng OT, Vasoo S (2026) The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: a systematic review and meta-analysis. JAC Antimicrob Resist 8(1). https:\/\/doi.org\/10.1093\/jacamr\/dlae001","DOI":"10.1093\/jacamr\/dlae001"},{"key":"6862_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107710","volume":"67","author":"P Pimenta-de-Souza","year":"2026","unstructured":"Pimenta-de-Souza P, da Ramos Oliveira Silva A, Sandes V, Rocha JL, Ribeiro VB, Costa SF, Levin AS, Moreira J (2026) Ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam for severe pediatric infections: a systematic review, meta-analysis and evidence map. Int J Antimicrob Agents 67:107710","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"6862_CR11","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1128\/AAC.00862-16","volume":"60","author":"JS Bradley","year":"2016","unstructured":"Bradley JS, Armstrong J, Arrieta A, Arguedas A, Saez-Llorens X, Ramilo O, Blumer JL, Giguere G, Noel GJ, Yogev R (2016) Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime\u2013avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother 60(10):6252\u20136259","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"6862_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P (2011) Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70(1):119\u2013123","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"6862_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"key":"6862_CR14","unstructured":"Centers for Disease Control and Prevention (2026) National healthcare safety network (NHSN) patient safety component manual: identifying healthcare-associated infections (HAI) for NHSN surveillance. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/2psc_identifyinghais_nhsncurrent.pdf.\u00a0Accessed 15 Feb 2026"},{"key":"6862_CR15","unstructured":"Centers for Disease Control and Prevention (2020) Pneumonia (ventilator-associated [VAP] and non-ventilator-associated pneumonia [PNEU]) event. CDC\/NHSN surveillance definitions. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/6pscvapcurrent.pdf.\u00a0Accessed 15 Feb 2026"},{"issue":"1","key":"6862_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP, Raad II, Rijnders BJA, Sherertz RJ, Warren DK (2009) Clinical practice guidelines for diagnosis and management of intravascular catheter-related infection. Clin Infect Dis 49(1):1\u201345","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6862_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/PCC.0000000000002198","volume":"21","author":"SL Weiss","year":"2020","unstructured":"Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Lemson J, Trask P, Tucci M, Kissoon N, Allen S et al (2020) Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med 21(2):52\u2013106","journal-title":"Pediatr Crit Care Med"},{"key":"6862_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1532608","volume":"16","author":"Q Lu","year":"2025","unstructured":"Lu Q, Zhang H, Pan X, Li Y, Wang J, Liu Z, Chen Y, Zhao M, Xu W, Zhou Y (2025) Treatment of pediatric CNS infection caused by carbapenem-resistant Klebsiella pneumoniae with ceftazidime\/avibactam: two case reports and literature review. Front Pharmacol 16:1532608","journal-title":"Front Pharmacol"},{"key":"6862_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jgar.2018.12.004","volume":"17","author":"E Matarac\u0131 Kara","year":"2019","unstructured":"Matarac\u0131 Kara E, Y\u0131lmaz M, \u00d6zbek \u00c7elik B (2019) In vitro activities of ceftazidime\/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates. J Glob Antimicrob Resist 17:137\u2013141","journal-title":"J Glob Antimicrob Resist"},{"key":"6862_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02367-18","volume":"63","author":"JJ Gaudereto","year":"2019","unstructured":"Gaudereto JJ, Perdig\u00e3o Neto LV, Leite GC, Oliveira MS, Costa SF, Levin AS (2019) Synergistic effect of ceftazidime\u2013avibactam with meropenem against panresistant, carbapenemase-harboring Acinetobacter baumannii and Serratia marcescens. Antimicrob Agents Chemother 63:e02367-18","journal-title":"Antimicrob Agents Chemother"},{"key":"6862_CR21","volume":"13","author":"S Alzaidi","year":"2025","unstructured":"Alzaidi S, Alharthi M, Alshammamri H, Alotaibi M, Alzahrani A, Alghamdi A, Alhazmi A, Almutairi M, Alotaibi A, Alnasser Y et al (2025) A new approach to treat carbapenem-resistant Acinetobacter baumannii bacteremia using sulbactam\u2013avibactam combination: a case report. ID Cases 13:e01234","journal-title":"ID Cases"},{"key":"6862_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis 75:187\u2013212","journal-title":"Clin Infect Dis"},{"key":"6862_CR23","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2024) Breakpoint tables for interpretation of MICs and zone diameters, version 14.0. EUCAST, V\u00e4xj\u00f6. https:\/\/www.eucast.org.\u00a0Accessed 15 Feb 2026"},{"issue":"2","key":"6862_CR24","first-page":"549","volume":"69","author":"H Giamarellou","year":"2014","unstructured":"Giamarellou H, Poulakou G, Antoniadou A, Kontopidou F (2014) Double-carbapenem treatment for carbapenemase-producing Klebsiella pneumoniae: a rational approach. J Antimicrob Chemother 69(2):549\u2013552","journal-title":"J Antimicrob Chemother"},{"key":"6862_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/mdr.2022.0247","volume":"29","author":"M Havan","year":"2023","unstructured":"Havan M, Kendirli T, Parlar \u00d6T, \u00d6zcan S, Yah\u015fi A, Erat T, \u00d6cal D, Guriz H, \u00d6zdemir H, Karahan ZC, \u00c7iftci E, \u0130nce E (2023) Clinical management of a pandrug-resistant OXA-48 Klebsiella pneumoniae infection in the pediatric intensive care unit. Microb Drug Resist 29:256\u2013262","journal-title":"Microb Drug Resist"},{"issue":"8","key":"6862_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Arrieta AC, Arguedas A, Saez-Llorens X, Ramilo O, Giguere G, Noel GJ, Yogev R (2019) Safety and efficacy of ceftazidime\u2013avibactam plus metronidazole in children with complicated intra-abdominal infection. Pediatr Infect Dis J 38(8):816\u2013824","journal-title":"Pediatr Infect Dis J"},{"key":"6862_CR27","first-page":"973","volume-title":"Red Book: 2024\u20132027 report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2024","unstructured":"American Academy of Pediatrics (2024) Antimicrobial therapy for specific pathogens and clinical syndromes. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (eds) Red Book: 2024\u20132027 report of the Committee on Infectious Diseases, 33rd edn. American Academy of Pediatrics, Itasca, pp 973\u20131007","edition":"33"},{"issue":"4","key":"6862_CR28","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P (2021) Ceftazidime\u2013avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther 10(4):1989\u20132034","journal-title":"Infect Dis Ther"},{"issue":"5","key":"6862_CR29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/antibiotics12050822","volume":"12","author":"F Sanz-Garc\u00eda","year":"2023","unstructured":"Sanz-Garc\u00eda F, Hernando-Amado S, Cabot G, Oliver A (2023) Molecular mechanisms of resistance to ceftazidime\/avibactam in clinical isolates. Antibiotics (Basel) 12(5):822","journal-title":"Antibiotics (Basel)"},{"key":"6862_CR30","volume":"15","author":"X Yang","year":"2025","unstructured":"Yang X, Li Y, Zhang Z, Wang Y, Liu J, Chen Z, Zhao L, Sun Y, Zhou Q, Huang Y (2025) Global trends of ceftazidime\u2013avibactam resistance in Gram-negative bacteria: a systematic review and meta-analysis. Front Cell Infect Microbiol 15:1510749","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"6862_CR31","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ (2016) Ceftazidime\u2013avibactam for the treatment of multidrug-resistant Klebsiella pneumoniae infections: clinical efficacy, resistance emergence, and outcomes. Clin Infect Dis 63(12):1615\u20131618","journal-title":"Clin Infect Dis"},{"key":"6862_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40272-025-00685-7","volume":"27","author":"A Castro-Fronti\u00f1\u00e1n","year":"2025","unstructured":"Castro-Fronti\u00f1\u00e1n A, Prieto-Tato LM, Caro-Teller JM, Garc\u00eda-Garc\u00eda MI, L\u00f3pez-Calleja AI, Garc\u00eda-Boyano M, Palacios-Baena ZR, Rodr\u00edguez-Ba\u00f1o J (2025) Ceftazidime\/avibactam for the treatment of infections in children: a case series of real-world use. Pediatr Drugs 27:427\u2013438","journal-title":"Pediatr Drugs"},{"issue":"5","key":"6862_CR33","first-page":"1","volume":"25","author":"ML Buck","year":"2019","unstructured":"Buck ML (2019) Use of ceftazidime\u2013avibactam in infants and children. Pediatr Pharmacother 25(5):1\u20136","journal-title":"Pediatr Pharmacother"},{"key":"6862_CR34","unstructured":"FDA Pediatric Review Team (2019) NDA\/BLA multi-disciplinary review and evaluation: ceftazidime\u2013avibactam. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pediatric\/400_206494S5_avibactam_ceftazidine_unireview_prea.pdf. Accessed 15 Feb 2026"},{"issue":"3","key":"6862_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318\u2013327","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"6862_CR36","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10096-024-04948-y","volume":"43","author":"OO Gundeslioglu","year":"2024","unstructured":"Gundeslioglu OO, Haytoglu Z, Gumus HH, Yildizdas D, Kendirli T, Havan M, Parlar \u00d6T, Y\u0131lmaz M, Kara EM (2024) Clinical experience with ceftazidime\/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children. Eur J Clin Microbiol Infect Dis 43(12):2361\u20132369","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06862-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-06862-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06862-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:54:16Z","timestamp":1776930856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-06862-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6862"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-06862-1","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}